3
Shared Docs
1
Same-Page
3 / 3
Mentions
nt pharmacy benefits manager."If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class," Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called "bad cholesterol", by as much as 60%, far more than the statin drugs al
worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M., Founder, President, and Chief Executive Officer, Regeneron. "Praluent represents the culmination of more than a decade of tireless work to tra
iant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class,” Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called “bad cholesterol”, by as much as 60%, far more than the statin drugs alo
Page: HOUSE_OVERSIGHT_025889 →worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M.D., Ph.D., Founder, President, and Chief Executive Officer, Regeneron. "Praluent represents the culmination of more than a decade of tireless work
Page: HOUSE_OVERSIGHT_025890 →iant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class,” Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called “bad cholesterol”, by as much as 60%, far more than the statin drugs alo
Page: HOUSE_OVERSIGHT_026363 →worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M.D., Ph.D., Founder, President, and Chief Executive HOUSE_OVERSIGHT_026364 --- PAGE BREAK --- Officer, Regeneron. "Praluent represents the culmi
Page: HOUSE_OVERSIGHT_026364 →Entities connected to both John Brennan and Leonard S. Schleifer

Jeffrey Epstein
PERSON
Donald Trump
PERSON
Pfizer
ORGANIZATION
the Food and Drug Administration
ORGANIZATION
Amgen
ORGANIZATIONRegeneron
PERSONTarrytown
LOCATION
the Cleveland Clinic
ORGANIZATION
Troy Brennan
PERSON
CVS Caremark
ORGANIZATIONPraluent
ORGANIZATION
Sanford C. Bernstein
ORGANIZATION
Olivier Brandicourt
PERSON
Matthew Herper
PERSONNissen
PERSONSchleifer
PERSON
Mark Schoenebaum
PERSON
Geoffrey Porges
PERSONVioxx
ORGANIZATIONthe Human Genome
ORGANIZATION